Landscape of novel coronavirus candidate vaccine development worldwide

Landscape of novel coronavirus candidate vaccine development worldwide

ON 13 August 2021

Summary

110 – Number of vaccines in clinical development

184 – Number of vaccines in pre-clinical development

how many vaccive against covid we have

Candidates in clinical phase . 3 leading platforms

PSProtein subunit3734%
VVnrViral Vector (non-replicating)1715%
DNADNA109%
 Candidates in clinical phase
all candidates in clinical phase

Number of doses, schedule and route of administration of candidates in clinical phase

Number of doses, schedule and route of administration of candidates in clinical phase covid

Landscape of candidate vaccines in clinical development

IDVaccine platform acronymVaccine platform descriptionType of candidate vaccineNumber of dosesScheduleDevelopersPhase
1IVInactivated virusCoronaVac; inactivated SARS-CoV-2 vaccine (vero cell)2Day 0 + 14Sinovac Research and Development Co., LtdPhase 4
2IVInactivated virusInactivated SARS-CoV-2 vaccine (Vero cell)2Day 0 + 21Sinopharm + China National Biotec Group Co + Wuhan Institute of Biological ProductsPhase 3
3IVInactivated virusInactivated SARS-CoV-2 vaccine (Vero cell), vaccine name BBIBP-CorV2Day 0 + 21Sinopharm + China National Biotec Group Co + Beijing Institute of Biological ProductsPhase 4
4VVnrViral vector (Non-replicating)ChAdOx1-S – (AZD1222)1-2Day 0 + 28AstraZeneca + University of OxfordPhase 4
Covishield
Vaxzevria
1-2Day 0 + 28University of OxfordPhase 1
5VVnrViral vector (Non-replicating)Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)1Day 0CanSino Biological Inc./Beijing Institute of BiotechnologyPhase 4
Ad5-nCoV
6VVnrViral vector (Non-replicating)Gam-COVID-Vac Adeno-based (rAd26-S+rAd5-S)2Day 0 + 21Gamaleya Research Institute ; Health Ministry of the Russian FederationPhase 3
Sputnik V COVID-19 vaccine
7VVnrViral vector (Non-replicating)Ad26.COV2.S1-2Day 0 or Day 0 +56Janssen PharmaceuticalPhase 4
8PSProtein subunitSARS-CoV-2 rS/Matrix M1-Adjuvant (Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M)
NVX-CoV2373
2Day 0 + 21NovavaxPhase 3
9RNARNA based vaccinemRNA-12732Day 0 + 28Moderna + National Institute of Allergy and Infectious Diseases (NIAID)Phase 4
10RNARNA based vaccineBNT162b2 (3 LNP-mRNAs ), also known as “Comirnaty”2Day 0 + 21Pfizer/BioNTech + Fosun PharmaPhase 4
11PSProtein subunitRecombinant SARS-CoV-2 vaccine (CHO Cell)2-3Day 0 + 28 or Day 0 + 28 + 56Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of SciencesPhase 3
12RNARNA based vaccineCVnCoV Vaccine2Day 0 + 28CureVac AGPhase 3
13IVInactivated virusSARS-CoV-2 vaccine (vero cells)2Day 0 + 28Institute of Medical Biology + Chinese Academy of Medical SciencesPhase 3
14IVInactivated virusQazCovid-in® – COVID-19 inactivated vaccine2Day 0 + 21Research Institute for Biological Safety Problems, Rep of KazakhstanPhase 3
15DNADNA based vaccineINO-4800+electroporation2Day 0 + 28Inovio Pharmaceuticals + International Vaccine Institute + Advaccine (Suzhou) Biopharmaceutical Co., LtdPhase 2/3
16DNADNA based vaccineAG0301-COVID192Day 0 + 14AnGes + Takara Bio + Osaka UniversityPhase 2/3
17DNADNA based vaccinenCov vaccine3Day 0 + 28 + 56Zydus CadilaPhase 3
18DNADNA based vaccineGX-19N2Day 0 + 28Genexine ConsortiumPhase 1/2
19IVInactivated virusWhole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152); Covaxin2Day 0 + 14Bharat Biotech International LimitedPhase 3
20PSProtein subunitKBP-COVID-19 (RBD-based)2Day 0 + 21Kentucky Bioprocessing Inc.Phase 1/2
21PSProtein subunitVAT00002: SARS-CoV-2 S protein with adjuvant2Day 0 + 21Sanofi Pasteur + GSKPhase 3
22RNARNA based vaccineARCT-021NDNDArcturus TherapeuticsPhase 2
23VLPVirus like particleRBD SARS-CoV-2 HBsAg VLP vaccine2Day 0 + 28Serum Institute of India + Accelagen Pty + SpyBiotechPhase 1/2
24IVInactivated virusInactivated SARS-CoV-2 vaccine (Vero cell)2Day 0 + 28Shenzhen Kangtai Biological Products Co., Ltd.Phase 3
25VVnrViral vector (Non-replicating)GRAd-COV2 (Replication defective Simian Adenovirus (GRAd) encoding S)1Day 0ReiThera + Leukocare + UnivercellsPhase 2/3
26VVnrViral vector (Non-replicating)VXA-CoV2-1 Ad5 adjuvanted Oral Vaccine platform2Day 0 + 28VaxartPhase 1
27VVnrViral vector (Non-replicating)MVA-SARS-2-S2Day 0 + 28University of Munich (Ludwig-Maximilians)Phase 1
28PSProtein subunitSCB-2019 + AS03 or CpG 1018 adjuvant plus Alum adjuvant (Trimeric subunit Spike Protein vaccine)2Day 0 + 21Clover Biopharmaceuticals Inc./GSK/DynavaxPhase 2/3
29PSProtein subunitCOVAX-19® Recombinant spike protein + adjuvant1Day 0 + 21Vaxine Pty Ltd./CinnaGen Co.Phase 2
SPIKOGEN®
30PSProtein subunitMVC-COV1901 (Spike-2P protein + adjuvant CpG 1018)2Day 0 + 28Medigen Vaccine Biologics + Dynavax + National Institute of Allergy and Infectious Diseases (NIAID)Phase 2
31PSProtein subunitFINLAY-FR1 anti-SARS-CoV-2 Vaccine (RBD + adjuvant)2Day 0 + 28Instituto Finlay de VacunasPhase 2
32PSProtein subunitFINLAY-FR-2 anti-SARS-CoV-2 Vaccine (RBD chemically conjugated to tetanus toxoid plus adjuvant)2Day 0 + 28Instituto Finlay de VacunasPhase 3
33PSProtein subunitEpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)2Day 0 + 21Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”Phase 3
34PSProtein subunitRBD (baculovirus production expressed in Sf9 cells) Recombinant SARS-CoV-2 vaccine (Sf9 Cell)2Day 0 + 28West China Hospital + Sichuan UniversityPhase 3
35PSProtein subunitIMP CoVac-1 (SARS-CoV-2 HLA-DR peptides)1Day 0University Hospital TuebingenPhase 1/2
36PSProtein subunitUB-612 (Multitope peptide based S1-RBD-protein based vaccine)2Day 0 + 28VaxxinityPhase 2/3
Viral vector (Replicating)V591-001 – Measles-vector based (TMV-o38)1-2Day 0 + 28Merck & Co. + Themis + Sharp & Dohme + Institute Pasteur + University of PittsburghPhase 1/2
37VVrViral vector (Replicating)DelNS1-2019-nCoV-RBD-OPT1 (Intranasal flu-based-RBD )2Day 0 + 28University of Hong Kong, Xiamen University and Beijing Wantai Biological PharmacyPhase 2
38RNARNA based vaccineLNP-nCoVsaRNA2NDImperial College LondonPhase 1
39RNARNA based vaccineSARS-CoV-2 mRNA vaccine (ARCoV)2Day 0 + 14 or
Day 0 + 28
Academy of Military Science (AMS), Walvax Biotechnology and Suzhou Abogen BiosciencesPhase 3
40VLPVirus like particleCoronavirus-Like Particle COVID-19 (CoVLP)2Day 0 + 21Medicago Inc.Phase 2/3
41VVr + APCViral vector (Replicating) + APCCovid-19/aAPC vaccine. The Covid-19/aAPC vaccine is prepared by applying lentivirus modification with immune modulatory genes and the viral minigenes to the artificial antigen presenting cells (aAPCs).3Day 0 + 14 + 28Shenzhen Geno-Immune Medical InstitutePhase 1
42VVnr + APCViral vector (Non-replicating) + APCLV-SMENP-DC vaccine. Dendritic cells are modified with lentivirus vectors expressing Covid-19 minigene SMENP and immune modulatory genes. CTLs are activated by LV-DC presenting Covid-19 specific antigens.1Day 0Shenzhen Geno-Immune Medical InstitutePhase 1/2
43PSProtein subunitAdimrSC-2f (recombinant RBD +/- Aluminium)NDNDAdimmune CorporationPhase 1
44DNADNA based vaccineCovigenix VAX-001 – DNA vaccines + proteo-lipid vehicle (PLV) formulation2Day 0 + 14Entos Pharmaceuticals Inc.Phase 1
45DNADNA based vaccineCORVax – Spike (S) Protein Plasmid DNA Vaccine2Day 0 + 14Providence Health & ServicesPhase 1
46RNARNA based vaccineChulaCov19 mRNA vaccine2Day 0 + 21Chulalongkorn UniversityPhase 1
47DNADNA based vaccinebacTRL-Spike oral DNA vaccine1Day 0Symvivo CorporationPhase 1
48VVnrViral vector (Non-replicating)Human Adenovirus Type 5: hAd5 S+N bivalent vaccine (S-Fusion + N-ETSD). E2b- Deleted Adeno.1-2Day 0 + 21ImmunityBio, IncPhase 1/2
49VVnrViral vector (Non-replicating)COH04S1 (MVA-SARS-2-S) – Modified vaccinia ankara (sMVA) platform + synthetic SARS-CoV-21-2Day 0 + 28City of Hope Medical Center + National Cancer InstitutePhase 1
50VVrViral vector (Replicating)rVSV-SARS-CoV-2-S Vaccine1Day 0Israel Institute for Biological ResearchPhase 1/2
51VVr + APCViral vector (Replicating) + APCDendritic cell vaccine AV-COVID-19. A vaccine consisting of autologous dendritic cells loaded with antigens from SARS-CoV-2, with or without GM-CSF1Day 0Aivita Biomedical, Inc.
National Institute of Health Research and Development, Ministry of Health Republic of Indonesia
Phase 1/2
52LAVLive attenuated virusCOVI-VAC1-2Day 0 or
Day 0 + 28
Codagenix/Serum Institute of IndiaPhase 1
53PSProtein subunitCIGB-669 (RBD+AgnHB)3Day 0 + 14 + 28 or Day 0 +28 + 56Center for Genetic Engineering and Biotechnology (CIGB)Phase 1/2
54PSProtein subunitCIGB-66 (RBD+aluminium hydroxide)3Day 0 + 14 + 28 or Day 0 +28 + 56Center for Genetic Engineering and Biotechnology (CIGB)Phase 3
55IVInactivated VirusVLA20012Day 0 + 21Valneva, National Institute for Health Research, United KingdomPhase 3
56PSProtein subunitBECOV22Day 0 + 28Biological E. LimitedPhase 1/2
57VVnrViral vector (Non-replicating)AdCLD-CoV19 (adenovirus vector)1Day 0Cellid Co., Ltd.Phase 1/2
58DNADNA based vaccineGLS-53102Day 0 + 56 or
Day 0 + 84
GeneOne Life Science, Inc.Phase 1/2
59PSProtein subunitRecombinant Sars-CoV-2 Spike protein, Aluminum adjuvanted (Nanocovax)2Day 0 + 21Nanogen Pharmaceutical BiotechnologyPhase 3
60PSProtein subunitRecombinant protein vaccine S-268019 (using Baculovirus expression vector system)2Day 0 + 21ShionogiPhase 1/2
Viral vector (Non-replicating)AdCOVID, Adenovirus-based platform expresses receptor-binding domain (RBD) of spike protein1-2Day 0Altimmune, Inc.Phase 1
61PSProtein subunitSARS-CoV-2-RBD-Fc fusion protein1-2University Medical Center Groningen + Akston Biosciences Inc.Phase 1/2
62IVInactivated VirusERUCOV-VAC, inactivated virus2Day 0 + 21Erciyes University, TurkeyPhase 3
63PSProtein subunitCOVAC-1 and COVAC-2 sub-unit vaccine (spike protein) + SWE adjuvant2Day 0 + 28University of SaskatchewanPhase 1/2
64PSProtein subunitGBP510, a recombinant surface protein vaccine with adjuvant AS03 (aluminium hydroxide)2Day 0 + 28SK Bioscience Co., Ltd. and CEPIPhase 1/2
65PSProtein subunitRazi Cov Pars, recombinant spike protein3Day 0 + 21 +51Razi Vaccine and Serum Research InstitutePhase 2
66IVInactivated VirusCOVID-19 inactivated vaccine2Day 0 + 14Shifa Pharmed Industrial CoPhase 2/3
67PSProtein subunitMF59 adjuvanted SARS-CoV-2 Sclamp vaccine2Day 0 + 28The University of QueenslandPhase 1
68DNADNA based vaccineCOVIGEN2Day 0 + 28University of Sydney, Bionet Co., Ltd
Technovalia
Phase 1
69DNADNA based vaccineCOVID-eVax, a candidate plasmid DNA vaccine of the Spike protein2Day 0 + 28Takis + Rottapharm BiotechPhase 1/2
70VVnrViral vector (Non-replicating)BBV154, Adenoviral vector COVID-19 vaccine1Day 0Bharat Biotech International LimitedPhase 1
71RNARNA based vaccinePTX-COVID19-B, mRNA vaccine2Day 0 + 28Providence TherapeuticsPhase 1
72IVInactivated virusInactivated (NDV-based) chimeric vaccine with or without the adjuvant CpG 10182Day 0 + 28The Government Pharmaceutical Organization (GPO); PATH; DynavaxPhase 1/2
73RNARNA based vaccineCoV2 SAM (LNP) vaccine. A self-amplifying mRNA (SAM) lipid nanoparticle (LNP) platform + Spike antigen2Day 0 + 30GlaxoSmithKlinePhase 1
74VLPVirus like particleVBI-2902a. An enveloped virus-like particle (eVLP) of SARS-CoV-2 spike (S) glycoprotein and aluminum phosphate adjuvant.2Day 0 + 28VBI Vaccines Inc.Phase 1/2
75PSProtein subunitSK SARS-CoV-2 recombinant surface antigen protein subunit (NBP2001) + adjuvanted with alum.2Day 0 + 28SK Bioscience Co., Ltd.Phase 1
76VVnrViral vector (Non-replicating)Chimpanzee Adenovirus serotype 68 (ChAd) and self-amplifying mRNA (SAM) vectors expressing spike alone, or spike plus additional SARS-CoV-2 T cell epitopes.2-3Day 0 + 14 + 28 or Day 0 +28 + 56 or Day 0 + 112Gritstone OncologyPhase 1
77RNARNA based vaccinemRNA-1273.351.
A lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized S protein of the SARS-CoV-2 B.1.351 variant.
3Day 0 or Day 0 + 28 or Day 56Moderna + National Institute of Allergy and Infectious Diseases (NIAID)Phase 4
78PSProtein subunitSpFN (spike ferritin nanoparticle) uses spike proteins with a liposomal formulation QS21 (ALFQ) adjuvant.2-3Day 0 + 28 + 180Walter Reed Army Institute of Research (WRAIR)Phase 1
79PSProtein subunitEuCorVac-19; A spike protein using the recombinant protein technology and with an adjuvant.2Day 0 + 21POP Biotechnologies and EuBiologics Co.,LtdPhase 1/2
80IVInactivated virusInactivated SARS-CoV-2 vaccine FAKHRAVAC (MIVAC)2Day 0 + 14 +/- 21Organization of Defensive Innovation and ResearchPhase 1
81LAVLive attenuated virusMV-014-212, a live attenuated vaccine that expresses the spike (S) protein of SARS-CoV-21Day 0Meissa Vaccines, Inc.Phase 1
82RNARNA based vaccineMRT5500, an mRNA vaccine candidate2Day 0 + 21Sanofi Pasteur and Translate BioPhase 2
83VLPVirus like particleSARS-CoV-2 VLP Vaccine2Day 0The Scientific and Technological Research Council of TurkeyPhase 2
Vaccine-Wuhan; Vaccine-Alpha variant; Vaccine-Wuhan+Alpha variant
84PSProtein subunitReCOV: Recombinant two-component spike and RBD protein COVID-19 vaccine (CHO cell).2Day 0 + 21Jiangsu Rec-BiotechnologyPhase 1
85RNARNA based vaccineDS-5670a, mRNA vaccine2Daiichi Sankyo Co., Ltd.Phase 1/2
86IVInactivated VirusKoçak-19 Inactivated adjuvant COVID-19 viral vaccine2Day 0 + 21Kocak Farma, TurkeyPhase 1
87VVnrViral vector (Non-replicating)COVIVAC. Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein +/- adjuvant CpG 10182Day 0 + 28Institute of Vaccines and Medical Biologicals, VietnamPhase 1/2
88VVnrViral vector (Non-replicating)SC-Ad6-1, Adneviral vector vaccine1-2Day 0 +/- 21Tetherex Pharmaceuticals CorporationPhase 1
89VLPVirus like particleABNCoV2 capsid virus-like particle (cVLP) +/- adjuvant MF592Day 0 + 28Radboud UniversityPhase 1
90PSProtein subunitRecombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)2Day 0 + 21Guangdong Provincial Center for Disease Control and Prevention/Gaozhou Center for Disease Control and PreventionPhase 2
91RNARNA based vaccineHDT-301: Self-replicating mRNA vaccine formulated as a lipid nanoparticle.2Day 0 + 28SENAI CIMATECPhase 1
92IVInactivated VirusAdjuvanted inactivated vaccine against SARS-CoV-22Day 0 + 21The Scientific and Technological Research Council of Turkey (TÜBITAK)Phase 1
93RNARNA based vaccinemRNA-12832Day 0 + 28ModernaTX, Inc.Phase 1
94PSProtein subunitRecombinant SARS-CoV-2 Vaccine (CHO cell)2Day 0National Vaccine and Serum Institute, ChinaPhase 1/2
95RNARNA based vaccineEXG-5003; a temperature-sensitive self-replicating RNA vaccine expressing the receptor binding domain of the SARS-CoV-2 spike protein.1Day 0Elixirgen Therapeutics, IncPhase 1/2
96IVInactivated VirusInactivated COVID-19 vaccine2Day 0 + 28KM Biologics Co., Ltd.Phase 1/2
97IVInactivated VirusLive recombinant Newcastle Disease Virus (rNDV) vector vaccine2Day 0 + 21Laboratorio Avi-MexPhase 1
98RNARNA based vaccinemRNA COVID-19 vaccine2TBDShanghai East Hospital and Stemirna TherapeuticsPhase 1
99PSProtein subunitCoVepiT vaccine: SARS-CoV-2 multi-target peptide vaccine (targeting Spike, M, N, and several non-structural proteins)1-2Day 0 +/- 21OSE ImmunotherapeuticsPhase 1
100VVnrViral vector (Non-replicating)Modified Vaccinia Virus Ankara (MVA) vector expressing a stabilized SARS-CoV-2 spike protein2Day 0 + 28German Center for Infection ResearchPhase 1/2
101PSProtein subunitCoV2-OGEN1, protein-based vaccine1-2Day 0 +/- 14USSF/VaxformPhase 1
102PSProtein subunitQazCoVac-P – COVID-19 Subunit Vaccine1-2Day 0 + 21Research Institute for Biological Safety ProblemsPhase 1/2
103RNARNA based vaccineLNP-nCOV saRNA-02 vaccine; Self-amplifying RNA (saRNA) encapsulated in lipid nanoparticles (LNP)2Day 0 + 28MRC/UVRI and LSHTM Uganda Research UnitPhase 1
104RNARNA based vaccinemRNA-1273.211. A multivalent booster candidate combining mRNA-1273 plus mRNA-1273.351.1Day 0ModernaTX, Inc.Phase 2/3
105PSProtein subunitRBD protein recombinant SARS-CoV-2 vaccine3Day 0 + 21 + 35Bagheiat-allah University of Medical SciencesPhase 1
106PSProtein subunitBaiya SARS-CoV-2 VAX1, a plant-based subunit vaccine
(RBD-Fc + adjuvant)
2Day 0 + 21Baiya Phytopharm Co., Ltd.Phase 1
107PSProtein subunitSCB-2020S, an adjuvanted recombinant SARS-CoV-2 trimeric S-protein (from B.1.351 variant)2Day 0 + 21Clover Biopharmaceuticals AUS Pty LtdPhase 2
108VVnrViral vector (Non-replicating)PIV5 vector that encodes the SARS-CoV-2 spike protein1Day 0CyanVac LLCPhase 1
109VVnrViral vector (Non-replicating)AZD2816; adenoviral vector ChAdOx platform and based on the Beta (B.1.351) variant2Day 0 + 28AstraZeneca + University of OxfordPhase 2/3
110PSProtein subunit202-CoV; SARS-CoV-2 spike trimer protein + adjuvant, CpG7909.2Day 0 + 28Shanghai Zerun Biotechnology + Walvax Biotechnology + CEPIPhase 1

References:

who.int https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines


About Eleanor Harris

Hi, there. It's my blog about nutritional solutions. I post the most helpful content in this topic ❤️ I got master degree 4 years ago at University of Otago in Dunedin, New Zealand. Now i work for Danone as Nutrition Executive

View all posts by Eleanor Harris →

Leave a Reply

Your email address will not be published. Required fields are marked *